Aesther Healthcare Acquisition Corp.

The report gives a qualifications statement but does NOT state whether the board determined her to be independent, whether she joins any committee, or what compensation she will receive — the disclosures a Rule 5605 audit committee analysis would need. It is signed by the CFO appointed three days earlier.

The finance function changed hands during an open restatement, a delinquent Form 10-Q and three live Nasdaq deficiencies, and the outgoing CFO's January 30 departure was disclosed only now, alongside the successor. The same person serves as both Chief Financial Officer and counsel under a single monthly fee, and she signs this report herself.

A second listing deficiency in six days, on a different standard from the January 11 minimum bid price notice. Unlike the bid price rule, this one carries no second compliance period: the filing states that if MVLS compliance is not regained by July 15, 2024 the company will receive written notification that its securities are subject to delisting, appealable to a Hearings Panel.

The third distinct Nasdaq problem for this registrant in two months, after the late Form 10-Q filing notice of November 22, 2023 and alongside the non-reliance restatement. A second 180-day period is available only if the company meets the market value of publicly held shares standard and all other initial listing standards except bid price, and notifies Nasdaq of an intent to cure, possibly by a reverse stock split — which the company says it may consider.

Nasdaq set two dates in the notice: a plan to regain compliance must be submitted no later than January 22, 2024, and the delinquent Form 10-Q must be filed on or before May 20, 2024. The notice has no immediate effect on listing or trading, though the filing states no assurance that further delay will not. Item 7.01 furnishes a November 29 press release announcing receipt of the notice. This follows the November 10 non-reliance determination on the March 31 and June 30, 2023 statements.

The withdrawal reaches beyond the two Form 10-Qs: it also covers the financial statements in Registration Statements on Form S-1 (No. 333-271392, effective June 22, 2023 and No. 333-272859, effective July 7, 2023) and any earnings releases, guidance or investor presentations describing them. The prepayment under the Vellar/Meteora/Polar OTC Equity Prepaid Forward Transaction moves from an asset to Stockholders' Deficit, with the prepaid forward value and minimum maturity consideration recorded as liabilities. Discussed with Deloitte & Touche LLP.

An equity-line amendment that prices issuance well below the $9.00 trigger, so drawing on it is dilutive at a fixed discount. The filing also states that no shares have yet been issued under the agreement, and separately (Item 8.01) that on October 4, 2023 the company entered a non-binding term sheet with its largest stockholder for convertible promissory notes of up to $10 million principal.

These are the terms that decide when the counterparty can unwind and at what price the company's obligation is struck, and they are being reset for one participant only — the filing states no other party's terms were amended. A $2.50 trigger and an $8.00 reset price sit far apart, and both are stated relative to a share the SPAC's holders acquired at a unit price this filing does not state. The report gives no figures for what is currently owed.

The company discloses how much of that facility is actually live: only one closing has occurred, a $7.56 million note, roughly 24,400 shares have been issued to satisfy accrued interest, and no part of the warrant has been exercised. It states that full conversion of the outstanding note at the CONVERSION PRICE NOW IN EFFECT would equate to about 2% of currently outstanding common stock, expressly noting that price may be adjusted — so the 2% is a snapshot, not a cap.

Approval would let convertible financing exceed a fifth of the share count, and because those covenants also block share repurchases and litigation settlements while the Notes are outstanding, the noteholders hold effective veto power over corporate actions. For AEHA-legacy holders with no trust to fall back on, this is a company whose capital structure and freedom of action are controlled by a single financing counterparty, and the dilution grows if the stock falls.

The repayment schedule is chained to the convertible-note financing: McKra is repaid out of proceeds from the first and second additional closings under the securities purchase agreement, so if those tranches do not fund the repayments do not fall due on those triggers. A backstop obligation applies to any capital raise generating at least $25,000,000. The company must also issue 25,000 shares to McKra for the amendment and register them within 30 days of issuance.

A floor-priced convertible is the term to watch: the registration definition the amendment adds sizes the share reserve on the assumption that the notes and a year of interest convert AT THE FLOOR PRICE, which is how the parties themselves quantify the maximum dilution. The filing gives the tranche structure and the amounts but not the floor price, the conversion price or the warrant terms, all of which sit in the notes and the agreement.

The extension is bought monthly rather than granted: the Sponsor or its affiliates must deposit an additional $0.045 per share into the Trust Account for each one-month extension until June 16, 2023, in exchange for a non-interest bearing, unsecured promissory note payable only on consummation of a business combination — so the sponsor is repaid only if a deal closes. The stated purpose is to allow time to complete the combination with Ocean Biomedical, Inc. announced in a Current Report dated August 31, 2022. The meeting day is left blank.

Two cash tests apply and one sits on the far side of closing: Closing AHAC Cash must meet the Minimum Cash Condition, and New Ocean Biomedical must have $50,000,000 after redemptions and after both parties' transaction expenses. Ocean Biomedical's holders are expected to hold about 64.5% assuming no redemptions, with the Sponsor and AHAC's officers and directors at about 20.0%, so AHAC would need 4,119,750 shares — 38.9% of the 10,600,000 public shares sold in the IPO. Dilution on top: up to 5,250,000 public warrants and 5,411,000 private placement warrants, both at $11.50.